Intensity of statin therapy and muscle symptoms: a network meta-analysis of 153 000 patients

Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials

(2021) Emily Herrett et al.   BMJ-British Medical Journal

N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects

(2020) Frances A. Wood et al.   NEW ENGLAND JOURNAL OF MEDICINE

Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis ( TRACE RA ): A multicenter, randomized, placebo controlled trial

(2019) George D. Kitas et al.   Arthritis & Rheumatology

Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France

(2019) Philippe Giral et al.   EUROPEAN HEART JOURNAL

Statin Use Over 65 Years of Age and All‐Cause Mortality: A 10‐Year Follow‐Up of 19 518 People

(2019) Sophia Eilat‐Tsanani et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk

(2019) François Mach et al.   EUROPEAN HEART JOURNAL

Introducing the ‘Drucebo’ effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions

(2018) Peter E. Penson et al.   Journal of Cachexia Sarcopenia and Muscle

Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase

(2017) Ajay Gupta et al.   LANCET

Protocol for analyses of adverse event data from randomized controlled trials of statin therapy

(2016) C. Reith et al.   AMERICAN HEART JOURNAL

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

(2016) Alberico L. Catapano et al.   EUROPEAN HEART JOURNAL

Statins for Prevention of Cardiovascular Disease in Adults

(2016) Roger Chou et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Statin Use for the Primary Prevention of Cardiovascular Disease in Adults

(2016) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Interpretation of the evidence for the efficacy and safety of statin therapy

(2016) Rory Collins et al.   LANCET

Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease

(2016) Salim Yusuf et al.   NEW ENGLAND JOURNAL OF MEDICINE

Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel

(2015) Maciej Banach et al.   Archives of Medical Science

Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

(2015) Erik S. Stroes et al.   EUROPEAN HEART JOURNAL

Automated generation of node-splitting models for assessment of inconsistency in network meta-analysis

(2015) Gert van Valkenhoef et al.   Research Synthesis Methods

A systematic review of statin-induced muscle problems in clinical trials

(2014) Harsha V. Ganga et al.   AMERICAN HEART JOURNAL

Discontinuation of Statins in Routine Care Settings

(2013) Huabing Zhang et al.   ANNALS OF INTERNAL MEDICINE

Comparative Tolerability and Harms of Individual Statins

(2013) Huseyin Naci et al.  

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

(2013)   LANCET

Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial

(2010)   LANCET

Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis

(2009) Bengt C. Fellström et al.   NEW ENGLAND JOURNAL OF MEDICINE

The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS)

(2008) Connie B Newman et al.   Diabetes & Vascular Disease Research

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

(2008) GISSI-HF investigators   LANCET

Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein

(2008) Paul M Ridker et al.   NEW ENGLAND JOURNAL OF MEDICINE